Listed price
$99
Supply
30-day supply; 30 lozenges described
Route
Sublingual lozenge
Care
Physician consultations included
Delivery
Free shipping advertised
Regulatory status
Compounded; not FDA-approved

A distinct route with a distinct price

The detailed Strut pricing card lists oral sermorelin at $99 for a 30-day supply. Elsewhere the page describes 30 sublingual lozenges per month. This review identifies it as a lozenge, rather than treating “oral” as a conventional swallowed tablet or as a cheaper form of the injection with identical effects.

The ingredient name alone does not settle how a finished product is absorbed or how much clinical benefit it provides. Ask the clinician what evidence supports the actual sublingual formulation and how that evidence compares with the alternatives being discussed.

Why a twenty-dollar difference is not the whole comparison

The companion injection is listed at $119, making the published difference $20 per billing period. That arithmetic is straightforward; the medical comparison is not. Needle-free administration may be a preference, but it does not demonstrate equivalent exposure, effectiveness or risk.

The two products should remain on separate rows in a cost worksheet. Record the route, supplied count or quantity, pharmacy and intended period before comparing the bill. If the clinician recommends one format for a particular reason, ask them to explain that reason rather than choosing solely on the smaller charge.

What is included around the lozenge

Strut says its price includes physician consultations and shipping, and advertises follow-ups and provider messaging. Confirm that the selected lozenge order carries those same inclusions and ask whether laboratory testing would be billed separately. A product can be less burdensome to administer while still requiring medical assessment and follow-up.

Check the complete ingredient list with the pharmacist if you have allergies or sensitivities. The active ingredient does not describe all components of a compounded lozenge. This guide has not inspected the finished product or independently tested its contents, potency or dissolution characteristics.

Storage and routine still require instructions

An oral format should not be assumed to be suitable for any travel or storage situation. Strut's page advises following pharmacy refrigeration instructions for its lozenges or vial. Obtain the exact label, beyond-use date and any permitted time away from refrigeration for the dispensed product.

Follow the prescriber's directions rather than adapting an injection schedule or a generic internet routine. If the product is difficult to use as directed, discuss that with the medical team before a refill. Altering the route or frequency on your own can make an already uncertain comparison less meaningful.

The subscription and evidence questions to resolve

The page advertises auto-refill and cancellation at any time. Ask when a forthcoming lozenge shipment becomes noncancelable, what happens if the prescription changes and whether unused dispensed medication is refundable. The answers matter even when the monthly price is clearly displayed.

Twelve unchanged $99 charges calculate to $1,188, before any unresolved costs. That figure does not imply proven long-term benefit or a recommendation for a year of therapy. The product is compounded and not FDA-approved. A useful enrollment decision combines the complete commercial terms with a candid discussion about the evidence for this specific route.

Useful distinctions

  • Clearly priced needle-free listing
  • Thirty-day supply described
  • Consultations and shipping included

Limitations to weigh

  • Clinical equivalence with injection not established
  • Storage instructions may still require refrigeration
  • Auto-refill and laboratory terms need review

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Strut Health: Sermorelin injection and oral lozenge Provider
  2. FDA: Understanding the Risks of Compounded Drugs Regulatory